RxSight Inc. Common Stock (RXST)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

RxSight is a commercial-stage medical device company selling a light-adjustable intraocular lens for cataract surgery. In fiscal 2025, the year ended 2025-12-31, revenue was $134.5 million and net loss was $38.9 million, or diluted EPS -$0.95. That compared with fiscal 2024, the year ended 2024-12-31, revenue of $139.9 million and net loss of $27.5 million, or diluted EPS -$0.71. Sales fell and the loss widened. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $27.2 million and net loss was $12.1 million, or diluted EPS -$0.29. This is not a compounding business yet. The technology may be differentiated, but I cannot verify a durable moat from these numbers; adoption must be weak enough that revenue is not growing. Financial health is poor: trailing free cash flow is -$27.2 million, FairStock's FCF yield is -14.4%, and FairStock's Altman Z-score is -0.66, which points toward distress. FairStock's Piotroski F-score is 4/9. On the positive side, debt is low, with D/E 0.04, and FairStock's P/B is 0.72 at the 2026-10-13 close of $4.53, so the market values it below accounting book. But a low P/B with continuing losses is not enough. FairStock's ROE is -17.34% and ROCE is -10.41%. The shares sit near the low of a 52-week range of $4.45-$13.22. As Graham would say, a bargain price without earning power or cash generation can be a trap. I need evidence that losses are shrinking and revenue is growing before calling this cheap.

In plain English: RxSight makes a special lens used in cataract surgery that can be adjusted with light after surgery. The business is still losing money and burning cash, and sales slipped in fiscal 2025 and again in the June 2026 quarter. At the latest close shown, $4.53, the stock trades for less than the value of its net assets on the books, but with no profits and negative cash flow, cheap on paper may not be cheap in reality.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer